Myron Z. Holubiak - 22 Jul 2021 Form 4 Insider Report for Citius Pharmaceuticals, Inc. (CTXR)

Signature
/s/ Alexander M. Donaldson, by power of attorney
Issuer symbol
CTXR
Transactions as of
22 Jul 2021
Net transactions value
$0
Form type
4
Filing time
26 Jul 2021, 17:02:58 UTC
Previous filing
24 May 2021
Next filing
13 Oct 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CTXR Common Stock 1,992,243 22 Jul 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTXR Options to Purchase Common Stock Award $0 +300,000 $0.000000 300,000 22 Jul 2021 Common Stock 300,000 $2.00 Direct F8
transaction CTXR Options to Purchase Common Stock Award $0 +10,000 $0.000000 10,000 22 Jul 2021 Common Stock 10,000 $2.00 See Footnote F8, F9
holding CTXR Warrant to Purchase Common Stock 784,314 22 Jul 2021 Common Stock 784,314 $1.15 Direct F1, F2
holding CTXR Options to Purchase Common Stock 26,667 22 Jul 2021 Common Stock 26,667 $8.10 Direct F3
holding CTXR Options to Purchase Common Stock 40,000 22 Jul 2021 Common Stock 40,000 $3.45 Direct F4
holding CTXR Options to Purchase Common Stock 150,000 22 Jul 2021 Common Stock 150,000 $1.62 Direct F5
holding CTXR Warrant to Purchase Common Stock 129,450 22 Jul 2021 Common Stock 129,450 $1.42 Direct F1, F2
holding CTXR Warrant to Purchase Common Stock 558,597 22 Jul 2021 Common Stock 558,597 $0.7700 Direct F1, F2
holding CTXR Options to Purchase Common Stock 175,000 22 Jul 2021 Common Stock 175,000 $0.6700 Direct F6
holding CTXR Options to Purchase Common Stock 200,000 22 Jul 2021 Common Stock 200,000 $1.01 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The warrant is fully vested and exercisable immediately.
F2 The purchase price of the warrants was included in the purchase price of the common stock reported in Table I.
F3 The option granted vested and became exercisable as follows: the option to purchase 2,667 shares of common stock of the Company (the "Common Stock") vested on October 1, 2015, and the balance of the option to purchase shares of Common Stock vested in twelve (12) equal installments commencing on December 31, 2015.
F4 One-third of the shares of the Company's common stock underlying the grant vest on the first anniversary of the vesting commencement date, September 13, 2018. The remaining shares of the Company's common stock underlying the grant vest in equal monthly installments at the end of each month for two years following the initial vest.
F5 One-third of the shares of the Company's common stock underlying the grant vest on each of the one-year, two-year and three-year anniversary of the vesting commencement date, September 4, 2018, provided that the Reporting Person provides continuous services to the Company as of each such vesting date.
F6 The options were granted on October 8, 2019. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F7 The options were granted on October 6, 2020. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F8 The options were granted on July 22, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F9 The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.